> Tripos is restructuring, laying off 76 workers at a U.K. facility and closing a temporary lab building. Report
> Tercica is raising $30 million through the sale of common stock. Release
> EU regulatory approval for Cytori's stem cell processing device has triggered an $11 million milestone payment from a joint venture it operates with Olympus. Report
> Chiron has won EU approval for the antibiotic Cubicin. Report
> Here's a profile of stem-cell start-up Plureon in Winston-Salem, NC: The biotech is staying mum for now about its research focus, but records indicate that Plureon has put the spotlight on "pluripotent" stem cells that--like embryonic stem cells--have the ability to morph into different types of cells, expanding its therapeutic reach. Report
> Proacta has started an early-stage trial of a new cancer drug and topped off its first round of venture capital. Release
> Alnylam is publicly offering more than 5 million shares of common stock. Release
> Caprion Pharmaceuticals will work with Berlex Biosciences to identify biomarkers. Release
> Quintiles Transnational today announced that it has signed an agreement to join a joint venture to commercialize pharmaceutical products in the Asia-Pacific region. Release
> Astex Therapeutics today announced that it has granted a non-exclusive, worldwide license to its Cytochrome P450 intellectual property to Pfizer. Release
> Chugai Pharmaceutical has decided to spin off its production operations currently conducted by its four plants in Ustunomiya, Ukima, Kamakura and Fujieda. Release
And Finally… Harvard stem cell researcher Douglas Melton discusses the added work that is required in a demanding field hampered by strict federal regulations. Article